Active Learning-Guided Hit Optimization for the Leucine-Rich Repeat Kinase 2 WDR Domain Based on In Silico Ligand-Binding Affinities
The leucine-rich repeat kinase 2 (LRRK2) is the most mutated gene in familial Parkinson's disease, and its mutations lead to pathogenic hallmarks of the disease. The LRRK2 WDR domain is an understudied drug target for Parkinson's disease, with no known inhibitors prior to the first phase of the Critical Assessment of Computational Hit-Finding Experiments (CACHE) Challenge. A unique advantage of the CACHE Challenge is that the predicted molecules are experimentally validated in-house. Here, we report the design and experimental confirmation of LRRK2 WDR inhibitor molecules. We used an active learning (AL) machine learning (ML) workflow based on optimized free-energy molecular dynamics (MD) simulations utilizing the thermodynamic integration (TI) framework to expand a chemical series around two of our previously confirmed hit molecules. We identified 8 experimentally verified novel inhibitors out of 35 experimentally tested (23% hit rate). These results demonstrate the efficacy of our free-energy-based active learning workflow to explore large chemical spaces quickly and efficiently while minimizing the number and length of expensive simulations. This workflow is widely applicable to screening any chemical space for small-molecule analogs with increased affinity, subject to the general constraints of RBFE calculations. The mean absolute error of the TI MD calculations was 2.69 kcal/mol, with respect to the measured <i>K</i><sub>D</sub> of hit compounds.
Authors
- Filipp Gusev (ORCID: https://orcid.org/0000-0002-1167-345X)
- P. Loppnau (ORCID: https://orcid.org/0009-0004-0002-355X)
- Olexandr Isayev (ORCID: https://orcid.org/0000-0001-7581-8497)
- C.H. Arrowsmith (ORCID: https://orcid.org/0000-0002-4971-3250)
- Sumera Perveen (ORCID: https://orcid.org/0000-0002-8898-9540)
- Levon Halabelian (ORCID: https://orcid.org/0000-0003-4361-3619)
- Albina Bolotokova
- Irene Chau (ORCID: https://orcid.org/0000-0002-2313-973X)
- Maria G. Kurnikova (ORCID: https://orcid.org/0000-0002-8010-8374)
- Elisa Gibson (ORCID: https://orcid.org/0000-0002-7112-337X)
- Francesco Gentile (ORCID: https://orcid.org/0000-0002-1847-5608)
- Evgeny Gutkin (ORCID: https://orcid.org/0000-0003-4522-6049)
- Rachel Harding (ORCID: https://orcid.org/0000-0002-1134-391X)
- Almagul Seitova
- Scott Houliston (ORCID: https://orcid.org/0000-0002-0113-0339)
- Fuqiang Ban
- Artem Cherkasov (ORCID: https://orcid.org/0000-0002-1599-1439)
- Matthieu Schapira (ORCID: https://orcid.org/0000-0002-1047-3309)
- Pegah Ghiabi
- Hong Zeng
- S. Benjamin Koby (ORCID: https://orcid.org/0009-0007-6643-7271)
- Suzanne Ackloo (ORCID: https://orcid.org/0000-0002-9696-1839)
- Fengling Li (ORCID: https://orcid.org/0000-0001-9530-2068)
- Ashley Hutchinson (ORCID: https://orcid.org/0000-0002-3481-8025)
Institutions
- University Health Network (CA)
- University of British Columbia (CA)
- University of Ottawa (CA)
- University of Toronto (CA)
- Princess Margaret Cancer Centre (CA)
- Health Net (US)
- Structural Genomics Consortium (CA)
- The Prostate Centre (GB)
- Ottawa Institute of Systems Biology
- Carnegie Mellon University (US)
Publication Details
- Journal
- Journal of Chemical Information and Modeling
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1021/acs.jcim.5c00588
- Citations
- 1
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 1.50
Funders
- Division of Chemistry